Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population

Fig. 1

Kaplan-Meier analysis of progression-free survival (a) PFS in all patients (b) PFS in the primary resistant population (c) PFS in the secondary resistant population. CI, confidence interval; HR, hazard ratio; m, months; PFS, progression-free survival; LX, lapatinib plus capecitabine; TBP, trastuzumab beyond progression

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us